Kamada (KMDA) Competitors $7.05 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$7.04 -0.01 (-0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. TVTX, BHVN, IMCR, CDTX, AUPH, WVE, JANX, EWTX, ARDX, and HROWShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Travere Therapeutics (TVTX), Biohaven (BHVN), Immunocore (IMCR), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Its Competitors Travere Therapeutics Biohaven Immunocore Cidara Therapeutics Aurinia Pharmaceuticals WAVE Life Sciences Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow Travere Therapeutics (NASDAQ:TVTX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Which has higher valuation and earnings, TVTX or KMDA? Kamada has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$333.87M4.66-$321.55M-$2.04-8.55Kamada$160.95M2.52$14.46M$0.3420.74 Do analysts prefer TVTX or KMDA? Travere Therapeutics currently has a consensus target price of $32.21, suggesting a potential upside of 84.71%. Kamada has a consensus target price of $13.00, suggesting a potential upside of 84.40%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Travere Therapeutics is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer TVTX or KMDA? In the previous week, Travere Therapeutics had 8 more articles in the media than Kamada. MarketBeat recorded 11 mentions for Travere Therapeutics and 3 mentions for Kamada. Kamada's average media sentiment score of 1.36 beat Travere Therapeutics' score of 0.91 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TVTX or KMDA? Travere Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Kamada has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Is TVTX or KMDA more profitable? Kamada has a net margin of 11.22% compared to Travere Therapeutics' net margin of -50.64%. Kamada's return on equity of 7.41% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-50.64% -717.68% -30.69% Kamada 11.22%7.41%5.18% Do insiders & institutionals hold more shares of TVTX or KMDA? 20.4% of Kamada shares are held by institutional investors. 4.2% of Travere Therapeutics shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryKamada beats Travere Therapeutics on 10 of the 16 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$405.45M$3.08B$5.73B$9.76BDividend YieldN/A2.24%4.40%4.08%P/E Ratio20.7420.7830.3826.03Price / Sales2.52348.83428.56103.94Price / Cash14.6043.2325.7828.79Price / Book1.569.809.706.08Net Income$14.46M-$54.08M$3.27B$265.64M7 Day Performance-2.62%4.92%3.95%3.11%1 Month Performance-8.68%3.64%3.81%0.39%1 Year Performance23.25%8.20%31.26%18.52% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.7388 of 5 stars$7.05flat$13.00+84.4%+23.3%$405.45M$160.95M20.74360Positive NewsTVTXTravere Therapeutics2.5121 of 5 stars$18.77-0.3%$32.21+71.6%+91.9%$1.68B$233.18M-9.20460News CoverageAnalyst DowngradeBHVNBiohaven3.7858 of 5 stars$16.02+2.0%$53.75+235.5%-64.2%$1.66BN/A-2.09239IMCRImmunocore1.7822 of 5 stars$32.31-1.7%$58.00+79.5%-8.9%$1.66B$310.20M-80.78320Positive NewsAnalyst ForecastCDTXCidara Therapeutics3.6057 of 5 stars$63.24-3.0%$64.14+1.4%+394.1%$1.65B$1.27M-5.6890Positive NewsAUPHAurinia Pharmaceuticals3.1372 of 5 stars$12.22-0.4%$12.00-1.8%+79.6%$1.62B$260.11M28.42300Positive NewsWVEWAVE Life Sciences4.8011 of 5 stars$9.74-0.2%$20.27+108.1%+73.2%$1.55B$108.30M-10.82240Positive NewsJANXJanux Therapeutics2.9632 of 5 stars$25.53+1.7%$91.89+259.9%-49.9%$1.51B$10.59M-14.1830News CoverageEWTXEdgewise Therapeutics2.2871 of 5 stars$14.00-1.1%$41.60+197.1%-26.0%$1.49BN/A-9.0360ARDXArdelyx4.2732 of 5 stars$5.81-2.7%$11.50+97.9%-4.6%$1.44B$386.15M-25.2690News CoverageInsider TradeHROWHarrow3.4432 of 5 stars$38.32-1.3%$64.67+68.8%-12.5%$1.44B$199.61M-153.28180Analyst Revision Related Companies and Tools Related Companies Travere Therapeutics Alternatives Biohaven Alternatives Immunocore Alternatives Cidara Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Janux Therapeutics Alternatives Edgewise Therapeutics Alternatives Ardelyx Alternatives Harrow Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access